# Trending Content OS — Daily Run Report
**Run Date:** 2026-09-24 | **Niche:** Health & Wellness

---

## 1. Preflight Summary

| Check | Status |
|---|---|
| All configs + skill sections loaded | ✅ |
| `site_niche` / `target_audience` set | ✅ |
| `site_url` | ⚠️ Not set — self-check skipped, competitor-list fallback used (configs/competitor_list.yaml) |
| `minimum_trend_strength_score` / `minimum_opportunity_score` | 50 / 55 ✅ valid |
| SerpAPI connected | ✅ |
| Google Trends | ✅ Available via injected pre-fetch (`search_velocity_source: google_trends`) |
| Deferred topics (`data/deferred_topics.yaml`) | None past `recheck_on` this run |
| Run history recurrence check | Ebola (DRC/Uganda) and FDA recalls have each appeared in 2 consecutive prior runs — flagged, not yet 3× threshold |
| **Decision** | `next_action: run_signal_listener` — proceed |

---

## 2. Google News Radar Coverage Summary

Clustered from 144 unique headlines (12 queries):

| Cluster | Disposition | Reason |
|---|---|---|
| **FDA thyroid tablet recall (Class I upgrade)** — [USA Today](https://www.usatoday.com/story/money/consumer-protection/recalls-alerts/2026/09/24/thyroid-tablet-medicine-recall-fda/91916444007/), [NewsNation](https://www.newsnationnow.com/health/fda-thyroid-tablet-recall-class-i/), [WGRZ](https://www.wgrz.com/article/news/nation-world/thyroid-medication-recall-upgraded-fda-vitruvias-therapeutics/507-7b634b7f-7828-4a8b-bd64-475ad06d2717) | **Retained (P1)** | Breaking, Google Trends breakout confirmed, multi-outlet convergence |
| **Mental health / adolescent gender gap** — [Nature](https://www.nature.com/articles/s41562-026-02577-3) | **Retained (P2)** | Fresh peer-reviewed study, direct DOI, rising Trends interest |
| **Clinical trial equity/access** — [STAT](https://www.statnews.com/2026/09/21/clinical-trials-website-pregnant-lactating-patients-checkbox/), [Word In Black](https://wordinblack.com/2026/09/black-patients-arent-avoiding-clinical-trials-they-often-arent-asked/), [Newswise](https://www.newswise.com/articles/expert-available-how-health-systems-can-help-address-america-s-clinical-trial-bottleneck) | **Retained (P3)** | Convergent multi-outlet health-equity narrative, no prior coverage |
| Secondary recalls (meat/USDA, ice cream, glutathione, tea, hand soap) | **Monitored** | Single-source or already covered; need corroboration/primary notice |
| HIV injectable vs. oral trial — [Medical Xpress](https://medicalxpress.com/news/2026-09-hiv-tablets-young-people-clinical.html) | **Monitored** | No traceable primary source in current signal set |
| Stanford anti-seizure drug/glioma study — [med.stanford.edu](https://med.stanford.edu/news/all-news/2026/09/seizure-drug-gliomas.html) | **Monitored** | Legit institutional primary source, deprioritized this run for capacity |
| PATHFINDER 2, GLP-1 misuse, Ebola/Congo, pro-nicotine wellness, egg/soap recalls, Alzheimer's cuts, brain-tumor metabolite, minibeam radiotherapy | **Rejected — existing** | Already covered in last 7 days, no material new development |
| Insurance/premiums, Medicaid fraud case, rural health funding, mental-health parity rule | **Rejected — excluded** | Pure policy/business/political healthcare, no evidence-based health angle |
| Local wellness events, gorilla wellness checkup, obituary, hospital expansion, WELL Health stock news, university partnership PR | **Rejected — off-category** | Local/business/novelty, no national health-audience value |
| OpenAI breach, MentalHealthBench, WHO AI-ethics report | **Rejected — off-category** | Tech/policy framing, weak consumer-health relevance |
| NYT wellness-spa injection death ruled homicide | **Monitored** | Single source, true-crime adjacent; revisit if corroborated as broader medspa-safety trend |

---

## 3. Signal Summary

```yaml
signal_summary:
  run_started_at: "2026-09-24T00:00:00Z"
  run_completed_at: "2026-09-24T00:00:00Z"
  total_signals_reviewed: 144
  total_signals_retained: 3
  total_rejected: 30
  google_trends_available: true
  search_velocity_source: "google_trends"
  rejection_breakdown:
    off_category: 14
    brand_safety: 0
    duplicate: 9
    weak_signal: 7
    unverified_claim: 0
    other: 0
  highest_priority_topic: "Vitruvias Therapeutics thyroid tablet recall (Class I)"
  strongest_signal_source: "Google Trends Trending Now + USA Today/NewsNation/WGRZ convergence"
  tools_unavailable: []
  notes: "Google News Radar clusters accounted for: FDA thyroid recall (retained), mental-health gender-gap study (retained), clinical trial equity (retained), secondary recalls + HIV trial + Stanford glioma study (monitored, thin sourcing), insurance/policy/local/PR clusters (rejected off-category), and 9 stories duplicating last-7-days coverage (rejected existing). site_url not configured — self-check skipped; competitor list used for SERP-gap context only."
```

---

## 4. Skill 02b — Health Claim Verification Gate Routing Summary

| Candidate | Risk Type | Result | Notes |
|---|---|---|---|
| Vitruvias thyroid recall | recall | **Pass** (breaking-recall exception) | 3 named outlets confirm same product/classification; confidence capped at Medium pending direct FDA.gov notice |
| Nature adolescent mental-health study | medical study | **Pass** | Direct journal URL/DOI-style ID is primary source |
| Clinical trial equity cluster | n/a | **Not applicable** | Systemic/access narrative, not a drug/treatment/supplement/recall/dosage claim |
| USDA meat recall | recall | **Monitor** | Single outlet (TODAY.com), no direct USDA/FSIS notice retrieved |
| So Delicious ice cream recall | recall | **Monitor** | Single outlet (NY Post) |
| Glutathione recall (3rd) | recall | **Monitor** | Single, non-trusted-tier outlet (MedShadow) |
| Tea recall | recall | **Monitor** | Single outlet (The Healthy) |
| HIV injectable vs. oral trial | clinical trial | **Monitor** | Secondary aggregator only, no traceable DOI/journal in current data |
| Stanford glioma anti-seizure drug study | drug/treatment claim | **Monitor** | Legit institutional primary source (med.stanford.edu) but deprioritized for capacity, not for gate failure |

---

## 5. Final Priority Board

| Priority | Topic | Timing | Trend | Opp. | Discover | Urgency | Confidence |
|---|---|---|---|---|---|---|---|
| **P1** | Vitruvias thyroid tablet recall (Class I) | Immediate | 73 | 76 | 4 | now | Medium |
| **P2** | Why girls have worse mental health than boys (Nature) | Short-term | 62 | 83 | 5 | today | Medium |
| **P3** | Clinical trials still exclude Black & pregnant patients | Scheduled | 54 | 70 | 4 | this_week | Medium |
| P5 | USDA meat recall / ice cream / glutathione / tea recalls / HIV injectable trial / Stanford glioma study | Monitor | — | — | — | — | Low–Medium |

```yaml
summary:
  total_topics: 3
  high_priority_count: 1
  immediate_actions: "Publish Vitruvias thyroid recall explainer today; verify FDA.gov notice before final publish."
```

---

## 6. Editorial Briefs — Retained Candidates

### P1 — Vitruvias Therapeutics Thyroid Tablet Recall (Class I)
```yaml
priority_level: P1
publish_timing: immediate
topic: "FDA upgrades Vitruvias Therapeutics thyroid tablet recall to Class I (highest risk)"
primary_entity: "Vitruvias Therapeutics"
signal_type: recall
allowed_category: "FDA and CDC regulatory updates"
trend_strength_score: 73
opportunity_score: 76
discover_score: 4
urgency: now
confidence: medium
content_status: new
source_count: 3
recommended_angle: "What the Class I thyroid recall means for patients — symptoms of dosing errors and what to do if you take this medication"
why_now: "FDA upgraded this recall to Class I today; confirmed by Google Trends real-time breakout plus USA Today, NewsNation, and WGRZ convergence — first day of peak search interest"
primary_headline: "FDA Upgrades Vitruvias Thyroid Tablet Recall to Highest Risk Level — What Patients Need to Know"
next_steps: "Verify official FDA recall number/NDC/lot codes via FDA.gov before publish; add patient guidance on over/under-dosing thyroid hormone symptoms"
notes: "⚠️ Integrity note: Primary FDA enforcement report not directly retrieved this run — verify via FDA.gov before publishing (breaking-recall exception applied)."
sources:
  - {publisher: "USA Today", url: "https://www.usatoday.com/story/money/consumer-protection/recalls-alerts/2026/09/24/thyroid-tablet-medicine-recall-fda/91916444007/", tier: 2}
  - {publisher: "NewsNation", url: "https://www.newsnationnow.com/health/fda-thyroid-tablet-recall-class-i/", tier: 2}
  - {publisher: "WGRZ", url: "https://www.wgrz.com/article/news/nation-world/thyroid-medication-recall-upgraded-fda-vitruvias-therapeutics/507-7b634b7f-7828-4a8b-bd64-475ad06d2717", tier: 2}
```

### P2 — Adolescent Mental Health Gender Gap (Nature)
```yaml
priority_level: P2
publish_timing: short_term
topic: "New Nature study explains why teen girls face worse mental health outcomes than boys"
primary_entity: "Nature (journal) — adolescent mental health gender-gap study"
signal_type: study_or_research
allowed_category: "mental health and psychology"
trend_strength_score: 62
opportunity_score: 83
discover_score: 5
urgency: today
confidence: medium
content_status: new
source_count: 1
recommended_angle: "Translate the Nature findings into practical guidance for parents/educators on the biological and social mechanisms behind the gap"
why_now: "Peer-reviewed study published this week; converges with rising Google Trends mental-health search interest (+5 this week)"
primary_headline: "New Study Reveals Why Teen Girls Face Higher Mental Health Risks Than Boys"
next_steps: "Pull named researchers/institution from full Nature article; secure secondary expert (clinical psychologist) commentary; confirm correlational vs. causal framing"
notes: "⚠️ Integrity note: Confirm study design (observational vs. causal) before publishing; avoid deterministic 'why' framing beyond what data supports."
sources:
  - {publisher: "Nature", url: "https://www.nature.com/articles/s41562-026-02577-3", tier: 1}
```

### P3 — Clinical Trial Access Equity (Concise Brief)
```yaml
priority_level: P3
publish_timing: scheduled
topic: "Clinical trials still exclude Black patients and pregnant/lactating people — a structural explainer"
primary_entity: "ClinicalTrials.gov / trial recruitment equity"
signal_type: audience_pain_point
allowed_category: "medical research and clinical trials"
trend_strength_score: 54
opportunity_score: 70
discover_score: 4
urgency: this_week
confidence: medium
content_status: new
source_count: 3
recommended_angle: "Structural explainer: Black patients and pregnant/lactating people aren't refusing trials — they're often not being asked"
why_now: "Three independent reports (STAT, Word In Black, Newswise) converged this week on trial-recruitment exclusion"
primary_headline: "Clinical Trials Still Leave Out the Patients Who Need Them Most — Here's Why"
next_steps: "Cite STAT/Word In Black reporting as anchor sources; add FDA/NIH diversity action plan guidance"
notes: "No major integrity flags; frame as structural/access barrier, not patient reluctance."
sources:
  - {publisher: "STAT News", url: "https://www.statnews.com/2026/09/21/clinical-trials-website-pregnant-lactating-patients-checkbox/"}
  - {publisher: "Word In Black", url: "https://wordinblack.com/2026/09/black-patients-arent-avoiding-clinical-trials-they-often-arent-asked/"}
  - {publisher: "Newswise", url: "https://www.newswise.com/articles/expert-available-how-health-systems-can-help-address-america-s-clinical-trial-bottleneck"}
```

---

## 7. Rejected Topics Log

| Topic | Reason |
|---|---|
| CDC PA measles death exclusion, GLP-1 misuse, PATHFINDER 2, Congo Ebola vaccination, pro-nicotine wellness, egg recall, Stanford two-organ brain study, FDA testosterone meeting, hand soap recall, FDA post-market study gaps, Alzheimer's funding cuts, brain tumor metabolite, DRC/Uganda Ebola spread, pancreatic liquid biopsy, intermittent fasting/Huntington's, minibeam radiotherapy | **Existing** — covered in last 7 days, no material new development |
| Insurance premiums (WaPo, Yale, Montana), mental health parity rule, Medicaid fraud case, rural health funding | **Off-category** — pure policy/business/insurance, no evidence-based health angle |
| Local wellness events (Black Men's Wellness Day, Haines, Marquette, UWM, UC Davis, USCG EAP), gorilla wellness checkup, Alice Walton hospital campus, Dr. Anthony Robbins obituary, UNC Ireland trip, UWL Ecuador program, Utah faculty research, Padres doctor honor, WELL Health platform launch, CNBC consumer spending | **Off-category** — local, PR, business, or novelty; no national health-audience value |
| OpenAI breach, MentalHealthBench, WHO AI-ethics report | **Off-category/weak audience fit** — tech/policy framing, not consumer health guidance |
| USDA meat recall, So Delicious ice cream recall, glutathione recall, tea recall, HIV injectable trial, Stanford glioma drug study, NYT medspa injection death, Ms. Magazine AI bias piece, pregnancy cravings study, Oklahoma infertility research, AI/device-recall study | **Monitor (weak signal)** — single-source or unverified primary source; revisit with corroboration |

---

## 8. Integrity Flags (Consolidated)

- ⚠️ **Vitruvias thyroid recall**: Primary FDA enforcement notice not directly retrieved — confirm NDC/lot numbers via FDA.gov before publishing.
- ⚠️ **Nature mental-health study**: Confirm observational vs. causal study design; avoid overstating mechanism in headline/framing.

---

## 9. Run Notes

- `site_url` unset — duplicate detection relied on competitor-list fallback (configs/competitor_list.yaml) plus the supplied Recent Coverage list; disclose in all P1–P3 briefs if published.
- Ebola (DRC/Uganda) and FDA recall stories have now appeared in 2 consecutive runs — approaching recurring/staleness threshold; watch for 3rd consecutive appearance.
- Four recall-type signals (USDA meat, ice cream, glutathione, tea) and one clinical trial claim (HIV injectable) were held at Skill 02b for insufficient primary-source corroboration — correctly excluded from scoring per protocol, not penalized within scores.
- `data/run_history.yaml` updated with today's entry (3 retained, 30 rejected/monitored, top topic: Vitruvias thyroid recall).